{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["LaRovere KL"],"funding":["NCATS NIH HHS","NIDDK NIH HHS"],"pagination":["536-547"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7936352"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["78(5)"],"pubmed_abstract":["<h4>Importance</h4>Coronavirus disease 2019 (COVID-19) affects the nervous system in adult patients. The spectrum of neurologic involvement in children and adolescents is unclear.<h4>Objective</h4>To understand the range and severity of neurologic involvement among children and adolescents associated with COVID-19.<h4>Setting, design, and participants</h4>Case series of patients (age <21 years) hospitalized between March 15, 2020, and December 15, 2020, with positive severe acute respiratory syndrome coronavirus 2 test result (reverse transcriptase-polymerase chain reaction and/or antibody) at 61 US hospitals in the Overcoming COVID-19 public health registry, including 616 (36%) meeting criteria for multisystem inflammatory syndrome in children. Patients with neurologic involvement had acute neurologic signs, symptoms, or diseases on presentation or during hospitalization. Life-threatening involvement was adjudicated by experts based on clinical and/or neuroradiologic features.<h4>Exposures</h4>Severe acute respiratory syndrome coronavirus 2.<h4>Main outcomes and measures</h4>Type and severity of neurologic involvement, laboratory and imaging data, and outcomes (death or survival with new neurologic deficits) at hospital discharge.<h4>Results</h4>Of 1695 patients (909 [54%] male; median [interquartile range] age, 9.1 [2.4-15.3] years), 365 (22%) from 52 sites had documented neurologic involvement. Patients with neurologic involvement were more likely to have underlying neurologic disorders (81 of 365 [22%]) compared with those without (113 of 1330 [8%]), but a similar number were previously healthy (195 [53%] vs 723 [54%]) and met criteria for multisystem inflammatory syndrome in children (126 [35%] vs 490 [37%]). Among those with neurologic involvement, 322 (88%) had transient symptoms and survived, and 43 (12%) developed life-threatening conditions clinically adjudicated to be associated with COVID-19, including severe encephalopathy (n = 15; 5 with splenial lesions), stroke (n = 12), central nervous system infection/demyelination (n = 8), Guillain-Barré syndrome/variants (n = 4), and acute fulminant cerebral edema (n = 4). Compared with those without life-threatening conditions (n = 322), those with life-threatening neurologic conditions had higher neutrophil-to-lymphocyte ratios (median, 12.2 vs 4.4) and higher reported frequency of D-dimer greater than 3 μg/mL fibrinogen equivalent units (21 [49%] vs 72 [22%]). Of 43 patients who developed COVID-19-related life-threatening neurologic involvement, 17 survivors (40%) had new neurologic deficits at hospital discharge, and 11 patients (26%) died.<h4>Conclusions and relevance</h4>In this study, many children and adolescents hospitalized for COVID-19 or multisystem inflammatory syndrome in children had neurologic involvement, mostly transient symptoms. A range of life-threatening and fatal neurologic conditions associated with COVID-19 infrequently occurred. Effects on long-term neurodevelopmental outcomes are unknown."],"journal":["JAMA neurology"],"pubmed_title":["Neurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome."],"pmcid":["PMC7936352"],"funding_grant_id":["K23 DK119463","UL1 TR001863"],"pubmed_authors":["Nofziger RA","Feldstein LR","Cengiz P","Overby PJ","Last Name FNAMIS","Wellnitz K","Carroll RW","Maamari M","McGuire JK","Bembea MM","Cholette JM","Gertz SJ","Singh AR","LaRovere KL","Ratner AJ","Schwartz SP","Lipton SV","Maddux AB","Gaspers MG","Heidemann SM","Babbitt CJ","McCulloh RJ","Smith LS","Kimura D","Fitzgerald JC","Carroll CL","Bradford TT","Riggs BJ","Zackai SP","Lansell AN","Bhoojhawon G","Randolph AG","Overcoming COVID-19 Investigators","Cullimore ML","Rowan CM","Mack EH","Tenforde MW","Hume JR","Levy ER","Patel MM","Kong M","Yager PH","Fink E","Munoz AC","Horwitz SM","Thomas NJ","Walker TC","Shein SL","Flori HR","McLaughlin GE","Kucukak S","Halasa NB","Young CC","Irby K","Sanders RC","Son MBF","Typpo KV","Mourani PM","Bowens C","Hobbs CV","Graciano AL","Montgomery VL","Kleinman LC","Koncicki ML","Marohn KL","Cvijanovich NZ","Chen SR","Harvey H","Li S","Schwarz AJ","Loftis LL","Carcillo J","Hall MW","Crandall H","Giuliano JS","Ackerman KG","Staat MA","Zinter MS","Michelson KN","Harwayne-Gidansky I","Spinella PC","Newhams MM","Walsh RF","Gillen JK","Keenaghan MA","Schuster JE","Sullivan JE","Fernandes ND","Hymes SR","Doymaz S","Coates BM","Clouser KN","Tarquinio KM","Poussaint TY","Havlin KM","Dapul H","Soma VL","Newburger JW"],"additional_accession":[]},"is_claimable":false,"name":"Neurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome.","description":"<h4>Importance</h4>Coronavirus disease 2019 (COVID-19) affects the nervous system in adult patients. The spectrum of neurologic involvement in children and adolescents is unclear.<h4>Objective</h4>To understand the range and severity of neurologic involvement among children and adolescents associated with COVID-19.<h4>Setting, design, and participants</h4>Case series of patients (age <21 years) hospitalized between March 15, 2020, and December 15, 2020, with positive severe acute respiratory syndrome coronavirus 2 test result (reverse transcriptase-polymerase chain reaction and/or antibody) at 61 US hospitals in the Overcoming COVID-19 public health registry, including 616 (36%) meeting criteria for multisystem inflammatory syndrome in children. Patients with neurologic involvement had acute neurologic signs, symptoms, or diseases on presentation or during hospitalization. Life-threatening involvement was adjudicated by experts based on clinical and/or neuroradiologic features.<h4>Exposures</h4>Severe acute respiratory syndrome coronavirus 2.<h4>Main outcomes and measures</h4>Type and severity of neurologic involvement, laboratory and imaging data, and outcomes (death or survival with new neurologic deficits) at hospital discharge.<h4>Results</h4>Of 1695 patients (909 [54%] male; median [interquartile range] age, 9.1 [2.4-15.3] years), 365 (22%) from 52 sites had documented neurologic involvement. Patients with neurologic involvement were more likely to have underlying neurologic disorders (81 of 365 [22%]) compared with those without (113 of 1330 [8%]), but a similar number were previously healthy (195 [53%] vs 723 [54%]) and met criteria for multisystem inflammatory syndrome in children (126 [35%] vs 490 [37%]). Among those with neurologic involvement, 322 (88%) had transient symptoms and survived, and 43 (12%) developed life-threatening conditions clinically adjudicated to be associated with COVID-19, including severe encephalopathy (n = 15; 5 with splenial lesions), stroke (n = 12), central nervous system infection/demyelination (n = 8), Guillain-Barré syndrome/variants (n = 4), and acute fulminant cerebral edema (n = 4). Compared with those without life-threatening conditions (n = 322), those with life-threatening neurologic conditions had higher neutrophil-to-lymphocyte ratios (median, 12.2 vs 4.4) and higher reported frequency of D-dimer greater than 3 μg/mL fibrinogen equivalent units (21 [49%] vs 72 [22%]). Of 43 patients who developed COVID-19-related life-threatening neurologic involvement, 17 survivors (40%) had new neurologic deficits at hospital discharge, and 11 patients (26%) died.<h4>Conclusions and relevance</h4>In this study, many children and adolescents hospitalized for COVID-19 or multisystem inflammatory syndrome in children had neurologic involvement, mostly transient symptoms. A range of life-threatening and fatal neurologic conditions associated with COVID-19 infrequently occurred. Effects on long-term neurodevelopmental outcomes are unknown.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 May","modification":"2024-11-15T21:04:32.258Z","creation":"2024-11-15T21:04:32.258Z"},"accession":"S-EPMC7936352","cross_references":{"pubmed":["33666649"],"doi":["10.1001/jamaneurol.2021.0504"]}}